Giuliana Vozza

Dec 8, 2024 | sciencedirect.com | Aparna Singhal |Jesus Frias |Xian-Zheng Zhang |Giuliana Vozza

Effective activation of sequential events in the cancer-immunity cycle (CIC) is a crucial prerequisite for achieving significant results in cancer immunotherapy [1], [2]. Affected by the immunosuppressive tumor microenvironment (TME), inadequate tumor-associated antigen presentation, limited tumor infiltration of T cells, and immune escape are responsible for the failure of CIC [3], [4].